Enrollment of women in HIV clinical trials in Rwanda

Abstract number: 1733_1064

Ackerson L., Abalikumwe F., Goble M., Horsburgh R.

Objective: To evaluate the proportion of women enrolled in clinical trials of investigational HIV therapies and assess factors that may influence enrollment of women.

Methods: Protocols were identified from a search of the AIDS Clinical Trials Information Service (ACTIS), a database that provides detailed information, including entry and exclusion criteria, on federally and privately sponsored clinical trials for HIV/AIDS therapies initiated between 2000 and 2004. Demographic and enrollment information was requested by letter from trial sponsors of all protocols.

Results: A total of 221 privately sponsored protocols were identified from the ACTIS database. Sponsors of 156 protocols provided demographic data stratified by gender. Enrollment of women in this sample ranged from 0% to 64% (mean 11.6%). Twenty-four trials enrolled no women. All were in phase 1 or 2 of development. All 24 protocols permitted enrollment of non-pregnant women. Sixteen of 24 studies required some form of birth control, including barrier methods, abstinence, and/or oral contraceptives. Eight of 24 protocols did not specify any reproductive-related inclusion/exclusion criteria. None of the 24 protocols had laboratory-based exclusion criteria that appeared to exclude women.

Conclusion: Factors other than gender-based eligibility criteria appear to be responsible for the failure of women to enroll in this sample of HIV clinical trials. To further explore this, The Project San Francisco (psf), Project UBUZIMA (with microbicide) and We-ACT, all located in Kigali, are developing an HIV investigational new drugs database to assess the recruitment and to promote the retention of women in current and future HIV clinical trials.

Session Details

Date: 31/03/2007
Time: 00:00-00:00
Session name: European Society of Clinical Microbiology and Infectious Diseases
Location: ICC, Munich, Germany
Presentation type:
Back to top